MedPath

A Controlled-Study on the Effect of a Combination of Fenofibrate and Metformin on Weight Loss and Weight Loss-Maintenance, in Obese Patients.

Phase 2
Completed
Conditions
Obesity
Registration Number
NCT00349635
Lead Sponsor
Solvay Pharmaceuticals
Brief Summary

To investigate the effect on body weight of a combination fenofibrate and metformin on top of a moderate balanced calorie-deficit diet.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
148
Inclusion Criteria
  • Both genders, BMI ≥ 30 kg/m² and <40 kg/m².
Exclusion Criteria
  • Known abnormal thyroid hormone levels, or high thyroid stimulating hormone (TSH) level.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Weight
Secondary Outcome Measures
NameTimeMethod
Waist and hip circumference

Trial Locations

Locations (3)

Site 3

🇫🇮

Kuopio, Finland

Site 1

🇫🇮

Helsinki, Finland

Site 2

🇫🇮

Oulu, Finland

© Copyright 2025. All Rights Reserved by MedPath